BeStock  
Stocks › Biotechnology › SEPN

Septerna SEPN

US equityMarket cap rank #2735Biotechnology
$38.61 −$0.59 (-1.51%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $38.61 0.00%
Open$38.72
Prev close$39.20
Day range$38.23 – $39.89
Volume374.3K
Market cap$1.84B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership100.4%-4.60 pts vs. prior quarter
Institutions holding202+6 vs. prior quarter
Insider trades (recent)29 buys / 21 sellsNet buying
Short interest7.18% of floatDays to cover 12.0 · as of 30 Oct 2026
Short-sale volume share24.5%5-day average of daily volume

Short-sale volume as % of daily volume

14%24%35%46%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$13.8K (11 inflow days, 9 outflow days).

Net flow by order size, last 20 sessions

−$1.9MSuper+$1.9MBig+$1.2MMid+$1.8MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 53.5% of shares outstanding.

Largest holders

  • Third Rock Ventures, LLC21.62%
  • RA Capital Management, L.P.11.57%
  • Driehaus Capital Management LLC9.32%
  • Samsara BioCapital LLC6.62%
  • BlackRock4.36%
  • The Goldman Sachs Group, Inc.3.61%
  • Artal Group S.A.3.58%
  • Vanguard Capital Management, LLC2.85%

By investor type

  • VC/PE Fund46.19%
  • Mutual Fund40.46%
  • Hedge Fund8.75%
  • Public Company4.41%
  • Individual/Insider2.81%
  • Private Company0.25%
  • Government Pension Fund0.21%
  • Insurance Company0.09%

Reported short interest has risen from 6.16% to 7.18% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
FMR Mutual Fund 2026/Q3 +842,396 1.8%
PRIMECAP Management Company Mutual Fund 2026/Q3 +186,879 2.8%
State Street Global Advisors Mutual Fund 2026/Q3 +145,516 1.7%
BlackRock Mutual Fund 2026/Q3 +142,515 4.4%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +132,615 2.8%
Morgan Stanley Public Company 2026/Q3 +72,629 0.4%
Morgan Stanley Investment Management Inc. Mutual Fund 2026/Q3 +72,629 0.4%
UBS Asset Management Mutual Fund 2026/Q3 +67,312 0.3%
Nordea Investment Management AB Mutual Fund 2026/Q3 +62,183 0.1%
Neuberger Berman Investment Advisers LLC Mutual Fund 2026/Q3 +76,979 0.2%
Neuberger Berman Investment Advisers LLC Mutual Fund 2026/Q3 +55,148 0.1%
Loomis, Sayles & Company L.P. Mutual Fund 2026/Q3 +624,752 1.3%
Janus Henderson Group plc Mutual Fund 2026/Q3 +416,746 2.7%
Algert Global LLC Hedge Fund 2026/Q3 +376,452 0.8%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +245,252 3.7%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
11 Nov 2026 Jeffrey Finer Chief Executive Officer Intent to Sell (Form 144) -66,000 $48.56 –
10 Nov 2026 R. Alan Ezekowitz Director Automatic Disposition -81,820 $51.90 35,600
14 Oct 2026 Elizabeth Bhatt President Derivative Exercise and Sale -4,000 $37.61 174,209
30 Sep 2026 Daniel Long Senior Vice President of Drug Discovery Intent to Sell (Form 144) -10,001 $39.13 –
30 Sep 2026 Samira Shaikhly Chief Human Resources Officer Intent to Sell (Form 144) -12,592 $39.13 –
7 Sep 2026 Rajiv Patni Chief Medical Officer Other Derivative Acquisition +275,000 $37.37 275,000
31 Aug 2026 Daniel Long Senior Vice President of Drug Discovery Derivative Exercise and Sale -3,333 $37.83 96,412
11 Aug 2026 RA Capital Management, L.P. Private Disposition -1,493,000 $42.50 5,502,858
11 Aug 2026 Third Rock Ventures, LLC Automatic Disposition -147,200 $51.08 10,280,050
10 Aug 2026 Elizabeth Bhatt President Derivative Exercise and Sale -25,000 $44.00 174,209
2 Aug 2026 Daniel Long Senior Vice President of Drug Discovery Derivative Exercise and Sale -3,334 $34.68 96,412
14 Jul 2026 Elizabeth Bhatt President Derivative Exercise and Sale -4,000 $33.99 174,209
30 Jun 2026 Daniel Long Senior Vice President of Drug Discovery Derivative Exercise and Sale -3,333 $34.81 96,412
28 Jun 2026 Samira Shaikhly Chief Human Resources Officer Derivative Exercise and Sale -2,178 $35.18 793
25 Jun 2026 R. Alan Ezekowitz Director Other Derivative Acquisition +15,000 $37.34 15,000
25 Jun 2026 RA Capital Management, L.P. Other Derivative Acquisition +15,000 $37.34 15,000
25 Jun 2026 Shalini Sharp Independent Director Other Derivative Acquisition +15,000 $37.34 15,000
25 Jun 2026 Jeffrey Tong Chairperson Other Derivative Acquisition +15,000 $37.34 15,000
25 Jun 2026 Bernard Coulie Independent Director Other Derivative Acquisition +15,000 $37.34 15,000
25 Jun 2026 Keith Gottesdiener Independent Director Other Derivative Acquisition +11,260 $37.34 11,260

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 3,352,395 7.2% 12.0
15 Oct 2026 3,522,956 7.5% 7.6
30 Sep 2026 3,096,190 6.6% 8.8
15 Sep 2026 2,894,002 6.2% 9.5
31 Aug 2026 2,718,332 5.8% 7.7
14 Aug 2026 2,874,690 6.2% 5.1

Discussion

No comments yet — be the first to weigh in on SEPN.

Sign in to join the discussion.

Scroll to Top